



300 NW 70th Avenue, Suite 102 • Plantation, Florida 33317
(954) 723-0057 Phone • (954) 723-0353 Fax
email: info@naceonline.com

**Clinical Updates for
Nurse Practitioners and
Physician Assistants: 2012/2013**



**February 2, 2013
Hilton Phoenix Airport
Phoenix, AZ**

**Course Directors
Deborah Paschal, CRNP
Gregg Sherman, MD**

**Activity Director
Michelle Frisch, MPH, CCMEP**

**Program Evaluation
February 13, 2013**

In February 2013, the National Association for Continuing Education (NACE) sponsored a CE activity, *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Phoenix, AZ.

This educational activity was designed to provide nurse practitioners and physician assistants the opportunity to learn about Osteoporosis, Psoriasis, Inflammatory Bowel Disease, Diabetes, and Atrial Fibrillation.

In planning this CE activity, NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

One hundred seventeen healthcare practitioners registered to attend *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Phoenix, AZ. Seventy five healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Seventy two completed forms were received. The data collected is displayed in this report.

CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society.


Physician assistants may receive a maximum of 6 hours of Category 1 credit for completing this program.

This program is approved for 6 contact hours of continuing education (which includes 4.75 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1209349

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.


What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	3	4.17	4.17
DO	2	2.78	2.78
NP	32	44.44	44.44
PA	25	34.72	34.72
RN	0	0.00	0.00
Other	10	13.89	13.89
Total Valid	72	100.00	100.00




What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	36	50.00	52.17
Endocrinology	3	4.17	4.35
Rheumatology	0	0.00	0.00
Pulmonology	0	0.00	0.00
Cardiology	4	5.56	5.80
Gastroenterology	3	4.17	4.35
OB/GYN	4	5.56	5.80
Other	19	26.39	27.54
Total Valid	69	95.83	100.00
Total Missing	3	4.17	
Total	72	100.00	




Upon completion of this activity, I can now - Identify appropriate candidates for BMD testing incorporating the FRAX 10-year fracture risk into treatment decisions; initiate pharmacologic therapy for patients who meet NOF guideline recommendations for pharmacologic management; implement education for dietary and supplemental calcium and vitamin D and exercises to prevent osteoporosis and related fractures; and recognize and overcome barriers to adherence and effectiveness of osteoporosis therapy:

Label	Frequency	Percent	Valid Percent
Yes	66	91.67	91.67
Somewhat	6	8.33	8.33
Not at all	0	0.00	0.00
Total Valid	72	100.00	100.00




Upon completion of this activity, I can now - Explain the current pathophysiologic mechanisms associated with the development of psoriatic disease; discuss the impact of psoriatic disease including its effects on mood, cardiovascular risk, quality of life, and other co-morbid conditions; recognize the percent of body surface area that categorizes a patient for topical or systemic therapy; and implement appropriate treatment plans for patients who are candidates for topical and/or systemic therapy:

Label	Frequency	Percent	Valid Percent
Yes	64	88.89	88.89
Somewhat	8	11.11	11.11
Not at all	0	0.00	0.00
Total Valid	72	100.00	100.00




Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and nonpharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; and use currently available laboratory tests to maximize benefit while minimizing toxicity:

Label	Frequency	Percent	Valid Percent
Yes	55	76.39	76.39
Somewhat	17	23.61	23.61
Not at all	0	0.00	0.00
Total Valid	72	100.00	100.00




Upon completion of this activity, I can now - Discuss the role of the incretin system in the pathophysiology of type 2 diabetes (T2DM); define the role of GLP-1 receptor agonist therapy in the treatment algorithm for T2DM; identify the features, benefits, and limitations of individual GLP-1 agonists; discuss the appropriate selection of GLP-1 receptor agonist therapy according to the glycemic disturbance most in need of correction:

Label	Frequency	Percent	Valid Percent
Yes	46	63.89	65.71
Somewhat	19	26.39	27.14
Not at all	5	6.94	7.14
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	




Upon completion of this activity, I can now - Use of the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); recognize the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify safe and effective use of new and emerging antithrombotic therapy for AF patients related to the risk stratification for stroke; and identify relevant patient characteristics to guide the selection and monitoring of antithrombotic therapy in patients with atrial fibrillation:

Label	Frequency	Percent	Valid Percent
Yes	53	73.61	84.13
Somewhat	10	13.89	15.87
Not at all	0	0.00	0.00
Total Valid	63	87.50	100.00
Total Missing	9	12.50	
Total	72	100.00	




Overall, I would rate this activity as:

Label	Frequency	Percent	Valid Percent
Excellent	34	47.22	47.89
Very Good	33	45.83	46.48
Good	4	5.56	5.63
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	




Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid Percent
Strongly Agree	30	41.67	42.25
Agree	40	55.56	56.34
Neutral	1	1.39	1.41
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	




Overall, this activity was effective in improving my knowledge in the content areas presented:

Label	Frequency	Percent	Valid Percent
Strongly Agree	36	50.00	50.00
Agree	36	50.00	50.00
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	72	100.00	100.00




As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid Percent
Strongly Agree	35	48.61	48.61
Agree	34	47.22	47.22
Neutral	3	4.17	4.17
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	72	100.00	100.00




How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	35	48.61	49.30
Somewhat likely	29	40.28	40.85
Unlikely	2	2.78	2.82
Not applicable	5	6.94	7.04
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	




When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	39	54.17	55.71
1-3 months	19	26.39	27.14
4-6 months	1	1.39	1.43
Not applicable	11	15.28	15.71
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Nelson Watts, MD (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	52	72.22	72.22
Very Good	18	25.00	25.00
Good	2	2.78	2.78
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	72	100.00	100.00




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Brad P. Glick, DO (Psoriasis):

Label	Frequency	Percent	Valid Percent
Excellent	55	76.39	78.57
Very Good	14	19.44	20.00
Good	1	1.39	1.43
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Gerald Dryden, MD (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	47	65.28	66.20
Very Good	18	25.00	25.35
Good	6	8.33	8.45
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Lisa Coco, CRNP, CDE (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	22	30.56	31.88
Very Good	18	25.00	26.09
Good	20	27.78	28.99
Fair	8	11.11	11.59
Unsatisfactory	1	1.39	1.45
Total Valid	69	95.83	100.00
Total Missing	3	4.17	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: William Matthai, MD (AFib):

Label	Frequency	Percent	Valid Percent
Excellent	43	59.72	75.44
Very Good	13	18.06	22.81
Good	1	1.39	1.75
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	57	79.17	100.00
Total Missing	15	20.83	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Nelson Watts, MD (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	61	84.72	84.72
Very Good	10	13.89	13.89
Good	0	0.00	0.00
Fair	1	1.39	1.39
Unsatisfactory	0	0.00	0.00
Total Valid	72	100.00	100.00




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Brad P. Glick, DO (Psoriasis):

Label	Frequency	Percent	Valid Percent
Excellent	59	81.94	83.10
Very Good	11	15.28	15.49
Good	1	1.39	1.41
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Gerald Dryden, MD (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	59	81.94	83.10
Very Good	10	13.89	14.08
Good	2	2.78	2.82
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Lisa Coco, CRNP, CDE (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	38	52.78	57.58
Very Good	13	18.06	19.70
Good	7	9.72	10.61
Fair	8	11.11	12.12
Unsatisfactory	0	0.00	0.00
Total Valid	66	91.67	100.00
Total Missing	6	8.33	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? William Matthai, MD (AFib):

Label	Frequency	Percent	Valid Percent
Excellent	47	65.28	77.05
Very Good	11	15.28	18.03
Good	1	1.39	1.64
Fair	0	0.00	0.00
Unsatisfactory	2	2.78	3.28
Total Valid	61	84.72	100.00
Total Missing	11	15.28	
Total	72	100.00	




Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent	Valid Percent
Topics covered	45	62.50	62.50
Location/ease of access	46	63.89	63.89
Faculty	10	13.89	13.89
Earn CME credits	64	88.89	88.89
Total Valid	72	100.00	100.00



Future CE activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid Percent
Strongly agree	22	30.56	30.99
Agree	35	48.61	49.30
Neutral	13	18.06	18.31
Disagree	1	1.39	1.41
Strongly Disagree	0	0.00	0.00
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	



What is your professional degree?

Comment
NMD
PA Student
PA Student
PA Student
PA Student
PA Student
PA Student
CCP
PA Student
PA Student

What is your specialty?

Comment
HIV/AIDS
Dermatology
Naturopathic
Pain Management
Radiation Oncology
Pain Management
Urology
Geriatrics
Internal Medicine
Geriatrics
College Health
Cardiac Surgery
Psychology
Correctional Health
Orthopedics
Orthopedic Surgery
Urgent Care

As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment
Able to recognize differences with some of the conditions covered
Strategies for topical steroids and vitamin D
Osteoporosis diagnosis
More information on medications my patients' will present to my office which will help me treat
Management of psoriasis
Osteoporosis treatment
FRAX tool for osteoporosis and treatment of psoriasis
Patient teaching and when to refer
Approach to initiating therapy
Psoriasis treatment
Look for systemic diseases
FRAX
Newer therapies of treatment
Use FRAX website
Osteoporosis treatment
Drug therapies and new lab tests
CHADS score
Treatment of psoriasis beyond skin level. Use of CHADS score to stratify risk
FRAX
Better risk stratification for OP
Prescribing practices
Use of FRAX and CHADS
Evaluation and assessment
More aggressive with osteoporosis treatment
FRAX tool and selection of OP meds. Screen my diabetes and hyperlipidemia patients for psoriatic arthritis
IBD and psoriasis treatment
Appropriate referral
Early intervention with biologics for IBD and psoriasis
Plan to utilize newer agents
CHAD scoring
Approaching and screening for osteoporosis. Screening for psoriatic arthritis
Effective management of osteoporosis and IBD
Managing diabetes more effectively and managing treatment regimens
Identifying psoriasis more effectively

What topics would you like to see offered as CE activities in the future?

Comment
More cardiology topics
COPD and hyperthyroidism

Comment
Headache management
Orthopedic related topics
Sports medicine and epilepsy
More on diabetes and IBS
HTN
Depression and hypertension
Women's Health
Pain management
Diabetes and cardiology
Eating disorders and oncology update
Cancer prevention
OB/GYN related topics and pelvic pain
Thyroid disease
Hypertension and RA
Neurological issues
Chronic pain
Opioid use and treatment
More cardiology topics
Hypertension
GU
HTN management
ENT
Updates in prostate cancer and asthma treatment
Infectious disease and lipids
More on dermatology
Treatment of asthma and allergic disease
Women's Health
More on obesity
Insulin resistant DM2 and thyroid issues
Drug addiction
More on pediatrics
Women's health issues
Dementia and Alzheimer's
HTN management
Hepatitis B and C management
Dermatology and radiology
HTN management
More on lipids
Testosterone replacement
Thyroid case studies
CHF surgery
Lupus

Comment
Depression and insomnia
Thyroid disease

Additional comments:

Comment
Great day-thank you
Thank you
Excellent topics and all were applicable to my practice
Excellent
Thank you for having this in Phoenix
Very good topics and would love to come again
Good job all
Great update
Excellent
I enjoyed this update and the speakers were great. Thank you for providing breakfast and lunch and free parking. Future conferences should include cost considerations for newer drugs/protocol for patients and less small group discussion
Very good lecture
Good conference
Moderator was excellent and I loved the interactive questions. Wish brand names could be listed next to generic names
Very good review of material-thank you
Great conference-thank you
Thank you
Well done
Thank you
Enjoyed everything
Great clinical information and speakers
Very good and practical information
Very good and thanks for the food
Great day
Good conference and I would attend again
Thanks for lunch
Great conference
Would have liked to hear more about lab testing in osteoporosis

Item Statistics:

	Title	Specialty	Learning Objectives1	Learning Objectives2	Learning Objectives3	Learning Objectives4	Learning Objectives5
Mean	3.65	3.77	1.08	1.11	1.24	1.41	1.16
Variance	1.38	10.12	0.08	0.10	0.18	0.39	0.14
Standard Deviation	1.18	3.18	0.28	0.32	0.43	0.63	0.37
Standard Error	0.14	0.38	0.03	0.04	0.05	0.07	0.05
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	6.00	8.00	2.00	2.00	2.00	3.00	2.00
Median	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	5.00	7.00	1.00	1.00	1.00	2.00	1.00

	Overall Activity	Enhancing My Confidence	Improving My Knowledge	Patient Care	Make Changes	Implement New Strategies	Nelson Watts MD {Osteo}
Mean	1.58	1.59	1.50	1.56	1.68	1.77	4.69
Variance	0.36	0.27	0.25	0.33	0.71	1.16	0.27
Standard Deviation	0.60	0.52	0.50	0.58	0.84	1.08	0.52
Standard Error	0.07	0.06	0.06	0.07	0.10	0.13	0.06
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	3.00
Maximum	3.00	3.00	2.00	3.00	4.00	4.00	5.00
Median	2.00	2.00	1.50	2.00	2.00	1.00	5.00
Range	2.00	2.00	1.00	2.00	3.00	3.00	2.00

	Brad P Glick DO {Psoriasis}	Gerald Dryden MD {IBD}	Lisa Coco CRNP {Diabetes}	William Matthai MD {AFib}	Nelson Watts MD {Osteo} Bias	Brad P Glick DO {Psoriasis} Bias	Gerald Dryden MD {IBD} Bias
Mean	4.77	4.58	3.75	4.74	4.82	4.82	4.80
Variance	0.21	0.42	1.16	0.23	0.23	0.18	0.22
Standard Deviation	0.46	0.65	1.08	0.48	0.48	0.42	0.47
Standard Error	0.05	0.08	0.13	0.06	0.06	0.05	0.06
Minimum	3.00	3.00	1.00	3.00	2.00	3.00	3.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	4.00	5.00	5.00	5.00	5.00
Range	2.00	2.00	4.00	2.00	3.00	2.00	2.00

	Lisa Coco CRNP {Diabetes} Bias	William Matthai MD {AFib} Bias	Reasons for Participating	Future CE Activities
Mean	4.23	4.66	-	1.90
Variance	1.13	0.66	-	0.55
Standard Deviation	1.06	0.81	-	0.74
Standard Error	0.13	0.10	-	0.09
Minimum	2.00	1.00	-	1.00
Maximum	5.00	5.00	-	4.00
Median	5.00	5.00	-	2.00
Range	3.00	4.00	-	3.00